A detailed history of Quadrant Capital Group LLC transactions in Morpho Sys Ag stock. As of the latest transaction made, Quadrant Capital Group LLC holds 5,620 shares of MOR stock, worth $101,722. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,620
Previous 5,572 0.86%
Holding current value
$101,722
Previous $55,000 83.64%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$8.6 - $18.18 $412 - $872
48 Added 0.86%
5,620 $101,000
Q4 2023

Feb 08, 2024

BUY
$4.55 - $9.9 $17,035 - $37,065
3,744 Added 204.81%
5,572 $55,000
Q3 2023

Nov 14, 2023

BUY
$6.72 - $8.6 $1,505 - $1,926
224 Added 13.97%
1,828 $12,000
Q2 2023

Aug 09, 2023

BUY
$3.95 - $7.74 $6,335 - $12,414
1,604 New
1,604 $11,000
Q3 2022

Nov 10, 2022

SELL
$4.14 - $22.13 $14,506 - $77,543
-3,504 Reduced 80.0%
876 $4,000
Q2 2022

Aug 09, 2022

BUY
$4.51 - $7.39 $6,638 - $10,878
1,472 Added 50.62%
4,380 $21,000
Q1 2022

May 06, 2022

SELL
$5.87 - $9.73 $11,646 - $19,304
-1,984 Reduced 40.56%
2,908 $20,000
Q4 2021

Feb 01, 2022

BUY
$9.08 - $12.45 $19,649 - $26,941
2,164 Added 79.33%
4,892 $46,000
Q3 2021

Nov 12, 2021

BUY
$11.76 - $19.51 $25,213 - $41,829
2,144 Added 367.12%
2,728 $32,000
Q2 2021

Aug 09, 2021

BUY
$18.95 - $23.95 $10,157 - $12,837
536 Added 1116.67%
584 $11,000
Q1 2021

May 12, 2021

SELL
$21.56 - $30.66 $431 - $613
-20 Reduced 29.41%
48 $1,000
Q4 2020

Feb 16, 2021

BUY
$24.81 - $30.33 $1,290 - $1,577
52 Added 325.0%
68 $2,000
Q3 2020

Nov 13, 2020

BUY
$30.28 - $35.72 $484 - $571
16 New
16 $1,000

Others Institutions Holding MOR

About MorphoSys AG


  • Ticker MOR
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 136,614,000
  • Market Cap $2.47B
  • Description
  • MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...
More about MOR
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.